Abstract: A medical device may include a shaft extending from a proximal end toward a distal end, the shaft including a lumen extending from the proximal end toward the distal end; a first stapling head at the distal end, the first stapling head configured to contain one or more staples, and the first stapling head having a block disposed within, and movable relative to, the first stapling head; a second stapling head at the distal end; and a pushing element extending through the lumen, the pushing element being movable from a first position to a second position, wherein transition of the pushing element from the first position to the second position urges the block to move toward second stapling head to deploy the one or more staples.

Abstract: A medical device comprising a shaft, a handle including a proximal portion and a distal portion, wherein the distal portion is fixed to a proximal portion of the shaft, and a channel extending from the handle into the shaft, wherein the channel includes a proximal channel and a distal channel, the proximal channel being rotatable relative to the distal channel and aligned with the distal channel throughout rotation of the proximal channel, wherein the proximal portion includes the proximal channel and the distal portion includes the distal channel, wherein the distal portion is rotatable relative to the proximal portion of the handle, and the shaft is configured to rotate with the distal portion of the handle.

Abstract: A system for controlling the flow of fluid through a medical device may include a medical device having a lumen that extends to a distal end of the medical device; a fluid source configured to supply fluid having a positive pressure to the lumen of the medical device; and a flow controller configured to apply a negative pressure to the fluid within the lumen, wherein the flow controller is triggered to apply the negative pressure upon a lowering of the positive pressure from the fluid source.

Abstract: A medical device may include a shaft extending from a proximal end toward a distal end, the shaft including a lumen extending from the proximal end toward the distal end; a first stapling head at the distal end, the first stapling head configured to contain one or more staples, and the first stapling head having a block disposed within, and movable relative to, the first stapling head; a second stapling head at the distal end; and a pushing element extending through the lumen, the pushing element being movable from a first position to a second position, wherein transition of the pushing element from the first position to the second position urges the block to move toward second stapling head to deploy the one or more staples.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Thymic stromal lymphopoietin, Vascular endothelial growth factor receptor 1, C—C motif chemokine 1, C—C motif chemokine 17, C—C motif chemokine 21, C—C motif chemokine 27, FLT-3 Ligand, Immunoglobulin G subclass 3, Interleukin-1 receptor type I, Interleukin-20, Interleukin-29, Interleukin-7, Platelet-derived growth factor A/B dimer, Platelet-derived growth factor A/A dimer, and MMP9:TIMP2 complex as diagnostic and prognostic biomarkers in renal injuries.

Abstract: Disclosed are methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury The methods use assays that detect one or more markers selected from the group consisting of Cytoplasmic aspartate aminotransferase, soluble Tumor necrosis factor receptor superfamily member 5, soluble CD40 Ligand, soluble C-X-C Motif chemokine 16, SIOO-AI2, Eotaxin, soluble E-selectin, Fibronectin, Granulocyte colony-stimulating factor, Granulocyte-macrophage colony-stimulating factor, Heparin-binding growth factor 2, soluble Hepatocyte growth factor receptor, Interleukin-I receptor antagonist, Interleukin-I beta, lnterleukun-10, lnterieukun-15, lnterieukun-3, Myeloperoxidase, Nidogen-I, soluble Oxidized low-density lipoprotein receptor I, Pappalysin-I, soluble P-selectin glycoprotein ligand I, Antileukoproteinase, soluble Kit ligand, Tissue inhibitor of metalloproteinasel, Tissue inhibitor of metalloproteinase 2, soluble Tumor n

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA 19-9, Insulin-like growth factor-binding protein 7, C—X—C motif chemokine 6, and C—C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

Abstract: A system for tracking a medical device, the system comprising a support having a channel extending therethrough, the channel being defined circumferentially by a surface, at least one encoder configured to track movement of a medical device through the channel, and one or more processors configured to receive input from the at least one encoder, receive an instruction from a user to store a zero position of the medical device relative to the channel, determine relative movement of the medical device from the zero position, and communicate the relative movement of the medical device from the zero position.

Abstract: The present disclosure relates generally to the field of medical devices and establishing fluid communication between body lumens. In particular, the present disclosure relates to devices and methods for establishing a controlled flow or access passage between body lumens.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Metalloproteinase inhibitor 1, Metalloproteinase inhibitor 2, Metalloproteinase inhibitor 4, C—C motif chemokine 15, C—C motif chemokine 18, C—C motif chemokine 23, and/or, C—C motif chemokine 24 as diagnostic and prognostic biomarker assays in renal injuries.

Abstract: The present disclosure relates generally to the field of medical devices and establishing fluid communication between body lumens. In particular, the present disclosure relates to devices and methods for placing the muscularis layers of first and second body lumens in contact to establish a long term or permanent open flow or access passage therebetween.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more markers selected from the group consisting of soluble p-selectin, protein NOV homolog, soluble epidermal growth factor receptor, netrin-4, haptoglobin, heat shock protein beta-1, alpha- 1 -antitrypsin, leukocyte elastase, soluble tumor necrosis factor receptor superfamily member 6, soluble tumor necrosis factor ligand superfamily member 6, soluble intercellular adhesion molecule 2, active caspase-3, and soluble platelet endothelial cell adhesion molecule as diagnostic and prognostic biomarkers in renal injuries.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a measured urine concentration of one or more of TIMP2 and IGFBP7 in combination with one or more of a measured serum creatinine and a measured urine output, which results are correlated to the renal status of the subject, and can be used for diagnosis, prognosis, risk stratification, staging, monitoring, categorizing and determination of further diagnosis and treatment regimens in subjects suffering or at risk of suffering from an injury to renal function, reduced renal function, and/or acute renal failure.

Abstract: The present disclosure relates generally to the field of medical devices and establishing fluid communication between body lumens. In particular, the present disclosure relates to devices and methods for establishing a controlled flow or access passage between body lumens.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of Follistatin-related protein 3, Basigin, Cathepsin B, and Tenascin as diagnostic and prognostic bio-marker assays in renal injuries.

Abstract: The present disclosure relates generally to the field of medical devices and establishing fluid communication between body lumens. In particular, the present disclosure relates to devices and methods for placing the muscularis layers of first and second body lumens in contact to establish a long term or permanent open flow or access passage therebetween.

Abstract: A medical device that comprises a rim defining a loop in a plane and defining a width measured perpendicular to the plane, at least one wire coupled to a distal end of the rim and extending proximally from the distal end out of the plane to a proximal end of the rim, the at least one wire having a cross-sectional dimension measured perpendicular to a longitudinal axis of the at least one wire, the cross-sectional dimension being smaller than the width of the rim, and a sheath configured to cover at least a portion of the rim and a portion of the at least one ware.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Coagulation factor VII, CA19-9, Insulin-like growth factor-binding protein 7, C—X—C motif chemokine 6, and C—C motif chemokine 13 as diagnostic and prognostic biomarkers in renal injuries.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect one or more of C-C motif chemokine 16, C-C motif chemokine 14, and Tyrosine-protein kinase receptor UFO as diagnostic and prognostic biomarker assays in renal injuries.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.